Zeria Pharmaceutical
4559.T4559.T · Stock Price
Historical price data
Overview
Zeria Pharmaceutical's mission is to contribute to human health through the development and provision of high-quality pharmaceutical and healthcare products. The company has achieved a robust market position in Japan, particularly in gastroenterology, and has built a sustainable business model through a diversified portfolio spanning prescription drugs, OTC products, and nutraceuticals. Its strategy focuses on lifecycle management of core assets, strategic in-licensing, and targeted expansion into high-growth Asian consumer health markets. Zeria's financial strength, evidenced by its significant market cap, supports steady R&D investment and strategic partnerships.
Technology Platform
Specialized expertise in gastrointestinal drug delivery systems and fermentation-based bioprocessing for nutraceuticals, focusing on formulation science and controlled-release technologies.
Pipeline
25| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Z-338 | Dyspepsia | Phase 3 | |
| Z-100 + Placebo | Cervical Cancer | Phase 3 | |
| Z-213 + Saccharated Ferric Oxide | Iron Deficiency Anemia | Phase 3 | |
| Z-213 | Iron Deficiency Anemia | Phase 3 | |
| Z-521 | Primary Hypophosphatemic Rickets | Phase 3 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Faces competition from global pharma giants in gastroenterology and from large multinationals in consumer healthcare. Its integrated model and deep domestic relationships are differentiators, but it must contend with pricing pressure and the innovative pipelines of larger rivals.